Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial
comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with
head and neck cancer following surgery. Lapatinib or placebo will be administered
post-operatively in combination with chemoradiotherapy followed by maintenance with lapatinib
or placebo for 1 year. The primary goal is to determine if lapatinib is effective at reducing
the recurrence of the disease in these high-risk patients.